{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:40:40Z","timestamp":1771051240129,"version":"3.50.1"},"reference-count":23,"publisher":"CSIRO Publishing","issue":"1","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":1913,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>Life expectancy in patients with schizophrenia is 15\u201320 years less than the general population. A dominant cause of morbidity and mortality in these patients is cardiovascular disease. Adverse consequences of modifiable cardiovascular risk factors can be reduced by regular monitoring of metabolic outcomes and intervention if required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>AIM<\/jats:title>\n                    <jats:p>To evaluate the metabolic screening in primary care for patients with schizoaffective disorders managed in primary care. To show the usefulness of combining simple practice audits in evaluating such areas of clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>An audit was undertaken in eight general practices in the Waikato and Bay of Plenty regions of New Zealand. Specifically, the monitoring of patients with schizophrenia or schizoaffective disorder whose antipsychotic medication was prescribed by primary care doctors was audited. Patient monitoring was compared to the guideline recommendation of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) and the Best Practice Advisory Centre (BPAC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>In total, 117 patients were included in the audit and none were fully monitored, as recommended by the RANZCP guidelines. Although two-thirds of patients had been evaluated for glycosylated haemoglobin (HbA1c), lipids, blood pressure, complete blood count and weight, &amp;lt;10% of patients had had prolactin, waist circumference or electrocardiogram measurements recorded. The proportion of patients having a HbA1c measured was also significantly higher in younger patients and patients who were non-M\u0101ori or enrolled with an urban practice (all P\u2009&amp;lt;\u20090.05). When using the simplified BPAC guidelines, half of all patients were correctly monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>These findings show there is room for improvement in the monitoring of patients receiving antipsychotic medication in primary care. This may indicate the need for clear guidance and general practitioner education around the monitoring requirements of these patients. Alternatively, a more simplified monitoring protocol may need to be developed. This audit has also shown that there is value in several practices completing the same audit and providing a larger cohort of patients for pooled data analysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/hc19023","type":"journal-article","created":{"date-parts":[[2020,2,23]],"date-time":"2020-02-23T19:20:47Z","timestamp":1582485647000},"page":"29-34","source":"Crossref","is-referenced-by-count":12,"title":["Metabolic screening in primary care for patients with schizophrenia or schizoaffective disorder and taking antipsychotic medication"],"prefix":"10.1071","volume":"12","author":[{"given":"Rawiri","family":"Keenan","sequence":"first","affiliation":[{"name":"AMedical Research Centre, University of Waikato, Hamilton, Waikato, New Zealand"},{"name":"BRoyal New Zealand College of General Practitioners, Wellington, New Zealand"},{"name":"CCorresponding author. Email: rkeenan@waikato.ac.nz"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Chepulis","sequence":"additional","affiliation":[{"name":"AMedical Research Centre, University of Waikato, Hamilton, Waikato, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Ly","sequence":"additional","affiliation":[{"name":"BRoyal New Zealand College of General Practitioners, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Carter","sequence":"additional","affiliation":[{"name":"BRoyal New Zealand College of General Practitioners, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhuan","family":"Lao","sequence":"additional","affiliation":[{"name":"AMedical Research Centre, University of Waikato, Hamilton, Waikato, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Asim","sequence":"additional","affiliation":[{"name":"BRoyal New Zealand College of General Practitioners, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijit","family":"Bhat","sequence":"additional","affiliation":[{"name":"BRoyal New Zealand College of General Practitioners, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivam","family":"Deo","sequence":"additional","affiliation":[{"name":"BRoyal New Zealand College of General Practitioners, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kee Ping","family":"Lim","sequence":"additional","affiliation":[{"name":"BRoyal New Zealand College of General Practitioners, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruzaimah","family":"Mohammed","sequence":"additional","affiliation":[{"name":"BRoyal New Zealand College of General Practitioners, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Scarlet","sequence":"additional","affiliation":[{"name":"BRoyal New Zealand College of General Practitioners, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Lawrenson","sequence":"additional","affiliation":[{"name":"AMedical Research Centre, University of Waikato, Hamilton, Waikato, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"issue":"8","key":"2025111814483342600_R1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1176\/ps.50.8.1036","article-title":"Life expectancy and causes of death in a population treated for serious mental illness.","volume":"50","author":"Dembling","year":"1999","journal-title":"Psychiatr Serv."},{"key":"2025111814483342600_R2","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry."},{"issue":"5","key":"2025111814483342600_R3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019590","article-title":"Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London.","volume":"6","author":"Chang","year":"2011","journal-title":"PLoS One."},{"issue":"6","key":"2025111814483342600_R4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067133","article-title":"Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries.","volume":"8","author":"Laursen","year":"2013","journal-title":"PLoS One"},{"key":"2025111814483342600_R5","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/273060","article-title":"Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia.","volume":"2014","author":"Khasawneh","year":"2014","journal-title":"Cardiol Res Pract."},{"key":"2025111814483342600_R6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fpsyt.2014.00137","article-title":"Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions.","volume":"5","author":"Ringen","year":"2014","journal-title":"Front Psychiatry."},{"issue":"1\u20133","key":"2025111814483342600_R7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.schres.2016.01.033","article-title":"Estimation of life expectancy, loss-of-life expectancy, and lifetime healthcare expenditures for schizophrenia in Taiwan.","volume":"171","author":"L\u00eang","year":"2016","journal-title":"Schizophr Res."},{"issue":"4","key":"2025111814483342600_R8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1192\/bjp.bp.117.203240","article-title":"Improving life expectancy in people with serious mental illness: should we place more emphasis on primary prevention?","volume":"211","author":"Ilyas","year":"2017","journal-title":"Br J Psychiatry."},{"key":"2025111814483342600_R9"},{"key":"2025111814483342600_R10","first-page":"27","article-title":"Dyslipidemia and atypical antipsychotic drugs.","volume":"65","author":"Casey","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"2025111814483342600_R11","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1016\/j.euroneuro.2006.06.005","article-title":"Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity.","volume":"16","author":"Van Gaal","year":"2006","journal-title":"Eur Neuropsychopharmacol."},{"issue":"6","key":"2025111814483342600_R12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jadohealth.2006.09.005","article-title":"Challenges in replicating interventions.","volume":"40","author":"Bell","year":"2007","journal-title":"J Adolesc Health."},{"issue":"2","key":"2025111814483342600_R13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s10597-012-9506-1","article-title":"Implementation of a weight loss program for Latino outpatients with severe mental illness.","volume":"49","author":"Mangurian","year":"2013","journal-title":"Community Ment Health J."},{"issue":"5","key":"2025111814483342600_R14","first-page":"1","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders.","volume":"50","author":"Royal Australian and New Zealand College of Psychiatrists","year":"2016","journal-title":"Aust N Z J Psychiatry."},{"issue":"2","key":"2025111814483342600_R15","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes.","volume":"27","author":"American Diabetes Association, American Psychiatric Association","year":"2004","journal-title":"Diabetes Care."},{"key":"2025111814483342600_R16","unstructured":"Best Practice Advisory Centre. Monitoring for metabolic disorders in patients taking antipsychotic drugs. Dunedin, NZ: Best Practice Advisory Centre; 2007. [cited 2018 December]. Available from: https:\/\/bpac.org.nz\/magazine\/2007\/february\/antipsychotics.asp"},{"key":"2025111814483342600_R17","unstructured":"National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. London, UK: NIHCE; 2014; [cited 2018 December]. Available from: https:\/\/www.nice.org.uk\/guidance\/cg178\/chapter\/1-Recommendations#care-across-all-phases"},{"issue":"6","key":"2025111814483342600_R18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1176\/appi.ps.002542012","article-title":"Primary care providers\u2019 views on metabolic monitoring of outpatients taking antipsychotic medication.","volume":"64","author":"Mangurian","year":"2013","journal-title":"Psychiatr Serv."},{"issue":"1","key":"2025111814483342600_R19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1017\/S003329171100105X","article-title":"Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.","volume":"42","author":"Mitchell","year":"2012","journal-title":"Psychol Med."},{"key":"2025111814483342600_R20"},{"issue":"7","key":"2025111814483342600_R21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1586\/14737175.2013.811901","article-title":"Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.","volume":"13","author":"Han","year":"2013","journal-title":"Expert Rev Neurother."},{"issue":"3","key":"2025111814483342600_R22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4068\/cmj.2016.52.3.159","article-title":"Second generation antipsychotics in the treatment of major depressive disorder: an update.","volume":"52","author":"Wang","year":"2016","journal-title":"Chonnam Med J."},{"key":"2025111814483342600_R23"}],"container-title":["The Journal of Primary Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/hc\/article-pdf\/12\/1\/29\/220204\/hc19023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/hc\/article-pdf\/12\/1\/29\/220204\/hc19023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T19:48:39Z","timestamp":1763495319000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/hc\/article\/12\/1\/29\/34256\/Metabolic-screening-in-primary-care-for-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,24]]},"published-print":{"date-parts":[[2020,3,30]]}},"URL":"https:\/\/doi.org\/10.1071\/hc19023","relation":{},"ISSN":["1172-6156"],"issn-type":[{"value":"1172-6156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]}}}